Search Results - "Venet, D"

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis by Bareche, Y., Venet, D., Ignatiadis, M., Aftimos, P., Piccart, M., Rothe, F., Sotiriou, C.

“…Recent efforts of genome-wide gene expression profiling analyses have improved our understanding of the biological complexity and diversity of triple-negative…”
Get full text

Linear mixed-effects models for central statistical monitoring of multicenter clinical trials by Desmet, L., Venet, D., Doffagne, E., Timmermans, C., Burzykowski, T., Legrand, C., Buyse, M.

“…Multicenter studies are widely used to meet accrual targets in clinical trials. Clinical data monitoring is required to ensure the quality and validity of the…”
Get full text

First report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts) by Aftimos, P.G., Antunes De Melo e Oliveira, A.M., Hilbers, F., Venet, D., Vingiani, A., Nili Gal Yam, E., Martinez, J.L., Ndozeng, J., Irrthum, A., Piccart, M.

Get full text

Dissecting the Akt/mTOR pathway in estrogen receptor positive breast cancers identifies phosphorylated Akt signature to be associated with luminal A and good prognosis in contrast to phosphorylated mTOR by Sonnenblick, A, Brohée, S, Pondé, N, Venet, D, Sotiriou, C

Get full text

The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab by Buisseret, L., Bareche, Y., Venet, D., Girard, E., Gombos, A., Emonts, P., Majjaj, S., Rouas, G., Serra, M., Debien, V., Agostinetto, E., Garaud, S., Willard-Gallo, K., Larsimont, D., Stagg, J., Rothé, F., Sotiriou, C.

“…Immune checkpoint blockade (ICB) in combination with chemotherapy improves outcome of patients with triple-negative breast cancer (TNBC) in metastatic and…”
Get full text

Identification of new phases in annealed Fe–18CrWTi ODS powders by Cayron, C., Montani, A., Venet, D., Carlan, Y. de

“…Fe –18CrWTi ODS steels are developed by CEA for the SFR generation IV program. The powders of a Fe –18CrWTi alloy reinforced by Y 2O 3 by mechanical milling…”
Get full text

Separation of samples into their constituents using gene expression data by Venet, D., Pecasse, F., Maenhaut, C., Bersini, H.

“…Gene expression measurements are a powerful tool in molecular biology, but when applied to heterogeneous samples containing more than one cellular type the…”
Get full text

Absence of a specific radiation signature in post-Chernobyl thyroid cancers by DETOURS, V, WATTEL, S, VENET, D, HUTSEBAUT, N, BOGDANOVA, T, TRONKO, M. D, DUMONT, J. E, FRANC, B, THOMAS, G, MAENHAUT, C

“…Thyroid cancers have been the main medical consequence of the Chernobyl accident. On the basis of their pathological features and of the fact that a large…”
Get full text

1811 Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial by Sotiriou, C, Venet, D, Fumagalli, D, Maetens, M, Rothé, F, Ignatiadis, M, Bradbury, I, Harbeck, N, Gomez, H, Chang, T.W, Coccia-Portugal, M.A, Di Cosimo, S, De Azambuja, E, De la Pena, L, Nuciforo, P, Armour, A, Eidtmann, H, Baselga, J, Piccart, M, Loi, S

Get full text

PP48 A proliferation measure integrates the outcome-related information contained in the breast cancer transcriptome by Detours, V, Venet, D, Weiss-Solis, D, Bersini, H, Dumont, J, Maenhaut, C

Get full text

Abstract P2-07-02: Uncovering TNBC molecular heterogeneity by applying integrative “omics” analyses with potential clinical implications by Bareche, Y, Venet, D, Rothe, F, Sotiriou, C

“…Abstract Introduction: Triple-negative breast cancer (TNBC), representing about 10-20% of all breast cancers (BC), is a heterogeneous disease characterized by…”
Get full text

136MO Differential benefit of low-dose cyclophosphamide and methotrexate maintenance chemotherapy among TNBC subtypes in the context of the IBCSG 22-00 study by Joaquin Garcia, A., Rediti, M., Venet, D., Majjaj, S., Kammler, R., Colleoni, M.A., Loi, S., Viale, G., Regan, M.M., Rothé, F., Sotiriou, C.

Get full text

1711P Spatial transcriptomics reveals substantial heterogeneity in TNBC tumor and stroma compartments with potential clinical implications by Wang, X., Venet, D., Lifrange, F., Larsimont, D., Rediti, M., Stenbeck, L., Gacquer, D., Dupont, F., Rouas, G., Serra, M., Lundeberg, J., Rothé, F., Sotiriou, C.

Get full text

Integrating spatial and single cell transcriptomics to identify and characterize biologically driven subgroups in invasive lobular carcinoma by Serra, M., Papagiannis, A., Rediti, M., Lifrange, F., Occelli, N., Collet, L., Vincent, D., Rouas, G., Fimereli, D., Craciun, L., Larsimont, D., Venet, D., Duhoux, F., Vikkula, M., Rothé, F., Sotiriou, C.

Get full text

Unravelling tumor heterogeneity in patients with HER2-low hormone receptor-positive breast cancer using spatial transcriptomics by Fimereli, D., Serra, M., Rediti, M., Lifrange, F., Occelli, N., Collet, L., Vincent, D., Rouas, G., Craciun, L., Larsimont, D., Venet, D., Vikkula, M., Duhoux, F.P., Rothé, F., Sotiriou, C.

Get full text

139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial by Rediti, M., Venet, D., Joaquin Garcia, A., Agbor-tarh, D., Maetens, M., Vincent, D., Majjaj, S., El-Abed, S., Liu, M.C., Di Cosimo, S., Piccart, M., Pusztai, L., Loi, S., Salgado, R.F., Viale, G., Rothé, F., Sotiriou, C.

Get full text

1726P Investigating adipocytes-tumor cells interaction and its effect on disease progression in lobular breast cancer with spatial transcriptomics by Serra, M., Collet, L., Rediti, M., Lifrange, F., Venet, D., Occelli, N., Vincent, D., Rouas, G., Larsimont, D., Craciun, L., Wang, X., Gacquer, D., Vikkula, M., Duhoux, F.P., Rothé, F., Sotiriou, C.

Get full text

43P Deciphering spatial expression of trop-2, HER2, and AR: Towards customized treatments in triple-negative breast cancer by Carausu, M., Lifrange, F., Venet, D., Rouas, G., Wang, X., Larsimont, D., Rothé, F., Sotiriou, C.

Get full text

Abstract P3-06-02: Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer by Nguyen, B, Venet, D, Lambertini, M, Desmedt, C, Salgado, R, Horlings, HM, Rothe, F, Sotiriou, C

“…Abstract Background: Although parity and age at first pregnancy are among the most known extrinsic factors that modulates breast cancer risk, their impact on…”
Get full text

2MO Development of a prognostic gene-expression signature for early stage HER2-positive breast cancer patients by Di Cosimo, S., Ciniselli, C.M., Sotiriou, C., Pogue-Geile, K., Fumagalli, D., de Azambuja, E., Venet, D., De Cecco, L., Pong, N., Cappelletti, V., Tagliabue, E., Wang, Y., Saura Manich, C., Nuciforo, P.G., Kuemmel, S., Pusztai, L., Daidone, M.G., Pizzamiglio, S., Pruneri, G., Verderio, P.

Get full text